Lugano Financial Advisors SA (LFA)’s Allogene Therapeutics ALLO Stock Holding History

Lugano Financial Advisors SA (LFA)’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$2K	Buy	+75	New	+$2.09K	﹤0.01%	154

Other funds holding ALLO

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

VV Manager Boston, Massachusetts $114M AUM 59.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lugano Financial Advisors SA (LFA)'s ALLO Position: Q2 2019 in Review

Lugano Financial Advisors SA (LFA) opened a new position in Allogene Therapeutics (ALLO) in Q2 2019: 75 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #154 among its holdings.

94 funds tracked by Wall St. Rank hold ALLO as of Q2 2019.

Lugano Financial Advisors SA (LFA) held 75 shares of Allogene Therapeutics worth $2K as of Q2 2019.
Allogene Therapeutics was a new Lugano Financial Advisors SA (LFA) position in Q2 2019.
Allogene Therapeutics made up ﹤0.01% of Lugano Financial Advisors SA (LFA)'s portfolio in Q2 2019, its #154 holding.
94 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2019.

Based on Lugano Financial Advisors SA (LFA)'s 13F filing for Q2 2019, filed 2 Aug 2019.